The direct-to-consumer genetic testing fog
By Timothy Caulfield,
Policy Options
| 05. 25. 2017
There is a direct-to-consumer (DTC) genetic testing company that gives parents the opportunity to uncover their kids’ “hidden” talents. You can (allegedly) find out if your child has the genetic propensity for things like dancing, passion, intelligence, self-reflection and even teenage romance. The company suggests that this information is valuable because it “will help you take control and maximize the development of your child,” including personalizing “discipline strategies” and career guidance so you can maximize your “returns on your investments” (because, let’s face it, kids are a financial sinkhole).
This is all scientifically absurd, of course. And any product based on the principle of having your kids do what you tell them seems destined to disappoint. Has the marketing team ever met a teenager?
But, despite the lack of evidence, these kooky kinds of DTC services continue to proliferate and have become big business. In China, for example, there has been a rise in genetic testing as many parents take their kids to “talent detection” facilities in the hope of gleaning information to inform education and career decisions.
There...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...